{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T02:00:09Z","timestamp":1768010409648,"version":"3.49.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,4]],"date-time":"2019-10-04T00:00:00Z","timestamp":1570147200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,10,4]],"date-time":"2019-10-04T00:00:00Z","timestamp":1570147200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n              <jats:p>Four large-scale trials in type 2 diabetes have shown that sodium-glucose cotransporter 2 (SGLT2) inhibitors prevent the occurrence of serious heart failure events. Additionally, the DAPA-HF trial demonstrated a benefit of dapagliflozin to reduce major adverse outcomes in patients with established heart failure with a reduced ejection fraction. The trial sheds light on potential mechanisms. In DAPA-HF, the benefits of dapagliflozin on heart failure were seen to a similar extent in both patients with or without diabetes, thus undermining the hypothesis that these drugs mitigate glycemia-related cardiotoxicity. The action of SGLT2 inhibitors to promote ketogenesis is also primarily a feature of the action of these drugs in patients with diabetes, raising doubts that enhanced ketogenesis contributes to the benefit on heart failure. Also, dapagliflozin does not have a meaningful effect to decrease circulating natriuretic peptides, and it did not potentiate the actions of diuretics in DAPA-HF; moreover, intensification of diuretics therapy does not reduce cardiovascular death, questioning a benefit of SGLT2 inhibitors that is mediated by an action on renal sodium excretion. Finally, although hematocrit increases with SGLT2 inhibitors might favorably affect patients with coronary artery disease, in DAPA-HF, the benefit of dapagliflozin was similar in patients with or without an ischemic cardiomyopathy; furthermore, increases in hematocrit do not favorably affect the clinical course of patients with heart failure. Therefore, the results of DAPA-HF do not support many currently-held hypotheses about the mechanism of action of SGLT2 inhibitors in heart failure. Ongoing trials are likely to provide further insights.<\/jats:p>","DOI":"10.1186\/s12933-019-0938-6","type":"journal-article","created":{"date-parts":[[2019,10,4]],"date-time":"2019-10-04T14:03:40Z","timestamp":1570197820000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Lessons learned from the DAPA-HF trial concerning the mechanisms of benefit of SGLT2 inhibitors on heart failure events in the context of other large-scale trials nearing completion"],"prefix":"10.1186","volume":"18","author":[{"given":"Milton","family":"Packer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,10,4]]},"reference":[{"key":"938_CR1","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","volume":"393","author":"TA Zelniker","year":"2019","unstructured":"Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Furtado RHM, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Sabatine MS. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393:31\u20139.","journal-title":"Lancet"},{"key":"938_CR2","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1911303","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, K\u00f8ber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, B\u011blohl\u00e1vek J, B\u00f6hm M, Chiang CE, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Duk\u00e1t A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O\u2019Meara E, Petrie MC, Vinh PN, Schou M, Tereshchenko S, Verma S, Held C, DeMets DL, Docherty KF, Jhund PS, Bengtsson O, Sj\u00f6strand M, Langkilde AM, DAPA-HF Trial Committees and Investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019. \n                    https:\/\/doi.org\/10.1056\/nejmoa1911303\n                    \n                  .","journal-title":"N Engl J Med"},{"key":"938_CR3","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.1161\/CIRCULATIONAHA.119.040130","volume":"139","author":"ET Kato","year":"2019","unstructured":"Kato ET, Silverman MG, Mosenzon O, Zelniker TA, Cahn A, Furtado RHM, Kuder J, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Bonaca MP, Ruff CT, Desai AS, Goto S, Johansson PA, Gause-Nilsson I, Johanson P, Langkilde AM, Raz I, Sabatine MS, Wiviott SD. Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus. Circulation. 2019;139:2528\u201336.","journal-title":"Circulation"},{"key":"938_CR4","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.1161\/CIRCULATIONAHA.119.040057","volume":"139","author":"GA Figtree","year":"2019","unstructured":"Figtree GA, R\u00e5dholm K, Barrett TD, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Matthews DR, Shaw W, Neal B. Effects of canagliflozin on heart failure outcomes associated with preserved and reduced ejection fraction in type 2 diabetes: results from the CANVAS program. Circulation. 2019;139:2591\u20133.","journal-title":"Circulation"},{"issue":"9","key":"938_CR5","doi-asserted-by":"publisher","first-page":"642","DOI":"10.3389\/fendo.2018.00642","volume":"29","author":"S Ducheix","year":"2018","unstructured":"Ducheix S, Magr\u00e9 J, Cariou B, Prieur X. Chronic O-GlcNAcylation and diabetic cardiomyopathy: the bitterness of glucose. Front Endocrinol (Lausanne). 2018;29(9):642. \n                    https:\/\/doi.org\/10.3389\/fendo.2018.00642\n                    \n                  .","journal-title":"Front Endocrinol (Lausanne)"},{"key":"938_CR6","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13855","author":"CCJ Dekkers","year":"2019","unstructured":"Dekkers CCJ, Sj\u00f6str\u00f6m CD, Greasley PJ, Cain V, Boulton DW, Heerspink HJL. Effects of the sodium-glucose co-transporter-2 inhibitor dapagliflozin on estimated plasma volume in patients with type 2 diabetes. Diabetes Obes Metab. 2019. \n                    https:\/\/doi.org\/10.1111\/dom.13855\n                    \n                  .","journal-title":"Diabetes Obes Metab."},{"key":"938_CR7","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.2337\/dc16-0542","volume":"39","author":"S Mudaliar","year":"2016","unstructured":"Mudaliar S, Alloju S, Henry RR. Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? A unifying hypothesis. Diabetes Care. 2016;39:1115\u201322.","journal-title":"Diabetes Care"},{"key":"938_CR8","doi-asserted-by":"publisher","first-page":"844","DOI":"10.14740\/jocmr2760w","volume":"8","author":"M Sano","year":"2016","unstructured":"Sano M, Takei M, Shiraishi Y, Suzuki Y. Increased hematocrit during sodium-glucose cotransporter 2 inhibitor therapy indicates recovery of tubulointerstitial function in diabetic kidneys. J Clin Med Res. 2016;8:844\u20137.","journal-title":"J Clin Med Res."},{"key":"938_CR9","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.diabres.2019.02.014","volume":"150","author":"B Sinha","year":"2019","unstructured":"Sinha B, Ghosal S. Meta-analyses of the effects of DPP-4 inhibitors, SGLT2 inhibitors and GLP1 receptor analogues on cardiovascular death, myocardial infarction, stroke and hospitalization for heart failure. Diabetes Res Clin Pract. 2019;150:8\u201316.","journal-title":"Diabetes Res Clin Pract"},{"key":"938_CR10","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.119.042929","author":"ME Nassif","year":"2019","unstructured":"Nassif ME, Windsor S, Tang F, Khariton Y, Husain M, Inzucchi SE, McGuire D, Pitt B, Scirica BM, Austin B, Drazner M, Fong M, Givertz MM, Gordon R, Jermyn R, Katz S, Lamba S, Lanfear D, LaRue S, Lindenfeld J, Malone M, Margulies KB, Mentz R, Mutharasan RK, Pursley M, Umpierrez G, Kosiborod M, DEFINE-HF Investigators. Dapagliflozin effects on biomarkers, symptoms, and functional status in patients with heart failure with reduced ejection fraction: the DEFINE-HF trial. Circulation. 2019. \n                    https:\/\/doi.org\/10.1161\/circulationaha.119.042929\n                    \n                  .","journal-title":"Circulation"},{"issue":"1","key":"938_CR11","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s12933-018-0775-z","volume":"17","author":"F Soga","year":"2018","unstructured":"Soga F, Tanaka H, Tatsumi K, Mochizuki Y, Sano H, Toki H, Matsumoto K, Shite J, Takaoka H, Doi T, Hirata KI. Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure. Cardiovasc Diabetol. 2018;17(1):132. \n                    https:\/\/doi.org\/10.1186\/s12933-018-0775-z\n                    \n                  .","journal-title":"Cardiovasc Diabetol."},{"key":"938_CR12","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.jjcc.2012.09.002","volume":"60","author":"K Watanabe","year":"2012","unstructured":"Watanabe K, Dohi K, Sugimoto T, Yamada T, Sato Y, Ichikawa K, Sugiura E, Kumagai N, Nakamori S, Nakajima H, Hoshino K, Machida H, Okamoto S, Onishi K, Nakamura M, Nobori T, Ito M. Short-term effects of low-dose tolvaptan on hemodynamic parameters in patients with chronic heart failure. J Cardiol. 2012;60:462\u20139.","journal-title":"J Cardiol"},{"key":"938_CR13","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s10741-011-9244-4","volume":"16","author":"R Valle","year":"2011","unstructured":"Valle R, Aspromonte N, Milani L, Peacock FW, Maisel AS, Santini M, Ronco C. Optimizing fluid management in patients with acute decompensated heart failure (ADHF): the emerging role of combined measurement of body hydration status and brain natriuretic peptide (BNP) levels. Heart Fail Rev. 2011;16:519\u201329.","journal-title":"Heart Fail Rev"},{"key":"938_CR14","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/ejhf.462","volume":"18","author":"K Damman","year":"2016","unstructured":"Damman K, Kjekshus J, Wikstrand J, Cleland JG, Komajda M, Wedel H, Waagstein F, McMurray JJ. Loop diuretics, renal function and clinical outcome in patients with heart failure and reduced ejection fraction. Eur J Heart Fail. 2016;18:328\u201336.","journal-title":"Eur J Heart Fail"},{"key":"938_CR15","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/S0735-1097(96)00214-8","volume":"28","author":"J Lommi","year":"1996","unstructured":"Lommi J, Kupari M, Koskinen P, N\u00e4veri H, Leinonen H, Pulkki K, H\u00e4rk\u00f6nen M. Blood ketone bodies in congestive heart failure. J Am Coll Cardiol. 1996;28:665\u201372.","journal-title":"J Am Coll Cardiol"},{"key":"938_CR16","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1161\/CIRCULATIONAHA.115.017355","volume":"133","author":"G Aubert","year":"2016","unstructured":"Aubert G, Martin OJ, Horton JL, Lai L, Vega RB, Leone TC, Koves T, Gardell SJ, Kr\u00fcger M, Hoppel CL, Lewandowski ED, Crawford PA, Muoio DM, Kelly DP. The failing heart relies on ketone bodies as a fuel. Circulation. 2016;133:698\u2013705.","journal-title":"Circulation"},{"key":"938_CR17","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1161\/CIRCULATIONAHA.118.036459","volume":"139","author":"R Nielsen","year":"2019","unstructured":"Nielsen R, M\u00f8ller N, Gormsen LC, Tolbod LP, Hansson NH, Sorensen J, Harms HJ, Fr\u00f8ki\u00e6r J, Eiskjaer H, Jespersen NR, Mellemkjaer S, Lassen TR, Pryds K, B\u00f8tker HE, Wiggers H. Cardiovascular effects of treatment with the ketone body 3-hydroxybutyrate in chronic heart failure patients. Circulation. 2019;139:2129\u201341.","journal-title":"Circulation"},{"key":"938_CR18","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.2337\/db15-1356","volume":"65","author":"E Ferrannini","year":"2016","unstructured":"Ferrannini E, Baldi S, Frascerra S, Astiarraga B, Heise T, Bizzotto R, Mari A, Pieber TR, Muscelli E. Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes. Diabetes. 2016;65:1190\u20135.","journal-title":"Diabetes"},{"key":"938_CR19","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1056\/NEJMoa1214865","volume":"368","author":"K Swedberg","year":"2013","unstructured":"Swedberg K, Young JB, Anand IS, Cheng S, Desai AS, Diaz R, Maggioni AP, McMurray JJ, O\u2019Connor C, Pfeffer MA, Solomon SD, Sun Y, Tendera M, van Veldhuisen DJ, RED-HF Committees, RED-HF Investigators. Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med. 2013;368:1210\u20139.","journal-title":"N Engl J Med."},{"key":"938_CR20","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1161\/CIRCULATIONAHA.119.040909","volume":"140","author":"M Packer","year":"2019","unstructured":"Packer M. Reconceptualization of the molecular mechanism by which sodium-glucose cotransporter 2 inhibitors reduce the risk of heart failure events. Circulation. 2019;140:443\u20135.","journal-title":"Circulation"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-019-0938-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12933-019-0938-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-019-0938-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,2]],"date-time":"2020-10-02T23:10:55Z","timestamp":1601680255000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-019-0938-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,4]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["938"],"URL":"https:\/\/doi.org\/10.1186\/s12933-019-0938-6","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,4]]},"assertion":[{"value":"21 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable. All authors agree to publication, and there are no permissions needed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Packer has recently consulted for Abbvie, Actavis, Akcea, Amgen, AstraZeneca, Boehringer Ingelheim, Cardiorentis, Daiichi Sankyo, Johnson & Johnson, NovoNordisk, Pfizer, Sanofi, Synthetic Biologics and Theravance.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"129"}}